Clinical Trial Update: IBAT Inhibitor A4250 for Cholestatic Pruritus [Phase 2]

View source ↗

Summary

A Phase 2 trial of the IBAT inhibitor A4250 for cholestatic pruritus in primary biliary cholangitis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• A4250 (odevixibat)

Snippet

Sponsor: Sahlgrenska University Hospital | Conditions: Biliary Cirrhosis, Primary | Phase 2 | Status: TERMINATED